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Abstract  Epidemic  keratoconjunctivitis  (EKC)  is  an  ocular  surface  infection  caused  by  ade-
novirus. To  date,  there  are  no  approved  topical  antiadenoviral  therapeutics  to  treat  EKC.
Recent research  reveals  that  treatment  with  topical  corticosteroids  for  symptomatic  relief  of
EKC enhances  adenovirus  replication  and  delays  cell  shedding  from  the  ocular  surface  which
delays adenovirus  elimination.  The  current  management  of  EKC  largely  revolves  around  accurate
diagnosis  of  the  condition  and  implementation  of  disinfection  protocol  to  prevent  its  spread.
Development  of  an  effective  antiviral  treatment  that  addresses  inﬂammation  and  does  not
prolong  viral  shedding  would  provide  signiﬁcant  beneﬁt.  The  literature  reports  on  a  variety
of therapeutics  that  could  potentially  satisfy  this  deﬁciency.  Topical  ganciclovir  and  povidone-
iodine combination  drops  have  shown  the  most  recent  potential,  but  both  therapeutics  need  to
be investigated  in  larger  scale  studies.  Until  an  antiadenoviral  option  is  produced,  the  treatment
of EKC  should  maintain  a  judicious  case  by  case  approach  aiming  to  contain  its  dissemination
and prevent  visual  consequences.
© 2012  Spanish  General  Council  of  Optometry.  Published  by  Elsevier  España,  S.L.  All  rights
reserved.
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Queratoconjuntivitis  epidémica:  revisión  de  los  conceptos  actuales  de  tratamiento
Resumen  La  queratoconjuntivitis  epidémica  (QCE)  consiste  en  una  infección  de  la  superﬁcie
ocular causada  por  adenovirus.  Hasta  la  fecha  no  existen  terapias  antiadenovíricas  aprobadas
para tratar  la  QCE.  Las  investigaciones  recientes  revelan  que  el  tratamiento  con  corticoes-
teroides tópicos  para  un  alivio  sintomático  de  la  QCE  aumenta  la  replicación  del  adenovirus
y retrasa  la  descamación  de  células  en  la  superﬁcie  ocular,  retardando  la  eliminación  del
virus. El  tratamiento  actual  de  la  QCE  gira  alrededor  del  diagnóstico  preciso  sobre  la  condi-adenovirus ción clínica  y  la  introducción  de  un  protocolo  de  desinfección  que  impida  su  diseminación.  El
desarrollo  de  un  tratamiento  antivírico  eﬁcaz  que  trate  la  inﬂamación  y  no  retrase  la  elim-
inación vírica  supondría  un  beneﬁcio  considerable.  La  literatura  reporta  gran  variedad  de
terapias que  podrían  satisfacer  potencialmente  esta  deﬁciencia.  La  aplicación  de  gotas  tópi-
cas con  una  combinación  de  ganciclovir  y  iodina-povidona  ha  demostrado  recientemente  su
potencial, aunque  ambas  terapias  precisan  investigarse  mediante  estudios  a  gran  escala.  Hasta
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que  aparezca  una  opción  antiadenovírica  el  tratamiento  de  la  QCE  debería  realizarse  utilizando
un enfoque  caso  a  caso,  a  ﬁn  de  contener  su  diseminación  y  prevenir  consecuencias  visuales.
© 2012  Spanish  General  Council  of  Optometry.  Publicado  por  Elsevier  España,  S.L.  Todos  los
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ntroduction
pidemic  keratoconjunctivitis  (EKC)  is  caused  by  the  ade-
ovirus  pathogen.1,2 Adenoviral  conjunctivitis  is  known  to
e  the  most  common  cause  of  red  eye  in  the  world.3 A
tudy  at  the  Wills  Eye  Hospital  emergency  room  found  a
2%  prevalence  of  adenoviral  conjunctivitis  amongst  all
atients  presenting  with  a  clinical  diagnosis  of  infectious
onjunctivitis,  while  various  other  studies  have  demon-
trated  a  prevalence  of  between  15%  and  70%  of  all
onjunctivitis  worldwide.1,3 More  than  50  different  adeno-
irus  serotypes  have  been  identiﬁed  and  divided  into  six
istinct  subgroups.2,4,5 Speciﬁc  adenovirus  serotypes  are
ssociated  with  various  types  of  ocular  infection.1,2 The
ost  common  types  of  adenoviral  conjunctivitis  include
KC,  pharyngoconjunctival  fever  and  nonspeciﬁc  follicular
onjunctivitis  (simple  adenoviral  conjunctivitis).1,6 EKC  is
ommonly  associated  with  adenovirus  serotypes  8,  19  and
7.2,4,6--8 EKC  is  considered  a  more  critical  form  of  adenoviral
eratoconjunctivitis  because  of  the  adverse  consequences  it
ay  have  on  visual  acuity.8
Due  to  the  epidemic  nature  of  EKC,  outbreaks  have  been
tudied  in  hospitals  and  health-care  settings.9--11 EKC  may
ccur  in  crowded  living  conditions  and  places  where  peo-
le  come  into  contact  with  one  another,  such  as  schools
nd  medical  practices.1,9 Transmission  of  the  virus  occurs  by
irect  contact  through  ocular  and  respiratory  secretions
r  by  indirect  contact  with  contaminated  instruments  or
olutions.11 Viral  particles  have  been  shown  to  be  infectious
n  nonporous  surfaces  for  upwards  of  one  month  and  there
s  evidence  that  transmission  can  occur  through  inanimate
ectors,  such  as  door  handles  and  tonometer  heads.4,9
The  dilemma  with  a  virus  such  as  EKC  is  that  patients
ho  have  contracted  the  disease  are  asymptomatic  dur-
ng  the  incubation  period  and  may  inadvertently  spread
he  virus.9 This  is  how  eye  doctors  may  unknowingly  act
s  vectors  and  contribute  to  the  spread  of  EKC  from
atient  to  patient.9 The  current  literature  demonstrates
hat  evidence-based  medicine  has  yet  to  proffer  a  sufﬁcient
herapeutic  method  to  treat  EKC.5 The  fact  remains  that
KC  is  highly  contagious.9,12
iscussion
KC  is  an  ocular  surface  infection  associated  with  a  marked
nﬂammatory  reaction,  and  symptoms  of  redness,  irritation,
earing,  blurry  vision  and  sensitivity  to  light.4 Clinical  signs
nclude  eyelid  edema,  follicular  conjunctivitis,  conjuncti-
al  edema  and  hyperemia,  epithelial  keratitis  and  often
reauricular  lymphadenopathy.6 The  onset  of  EKC  may  seem
apid  to  the  patient,  but  in  reality,  there  is  an  incubation
eriod  of  about  one  week  before  the  clinical  symptoms
resent.12 The  second  eye  is  often  affected  days  later  to
 much  lesser  degree.13 The  period  of  communicability  is
t
b
t
tFigure  1  Subepithelial  inﬁltrates  associated  with  EKC.
rom  late  in  the  incubation  phase  up  to  14  days  after  the
nset  of  the  disease.14 This  acute  phase  of  EKC  is  marked  by
 severe  conjunctivitis  and  lasts  from  two  to  four  weeks.14
fter  the  conjunctivitis  appears,  there  is  a period  of  viral
hedding  where  the  self-limiting  virus  is  gradually  cleared
rom  its  host.12 However,  before  the  virus  is  completely
hed,  the  inﬂammatory  reaction  of  the  conjunctiva  can
ecome  so  intense  that  it  results  in  a  pseudomembrane  and
otentially  permanent  symblepharon  formation  or  punctual
cclusion.6,12
The  symptoms  and  duration  of  EKC  can  vary  widely;  how-
ver,  it  is  distinguished  from  other  adenoviral  infections
hen  the  cornea  becomes  affected  by  the  development  of
ultifocal  subepithelial  inﬁltrates  (SEIs)6 (see  Fig.  1).  The
allmark  of  the  second,  more  chronic  phase  of  EKC  is  the
orneal  involvement.14 The  patient’s  presentation  of  mul-
ifocal  subepithelial  corneal  inﬁltrates  (SEI)  supports  the
iagnosis  of  EKC,  as  the  presence  of  SEIs  are  considered
athognomonic  for  the  diagnosis  of  EKC.6 These  inﬁltrates
re  typically  observed  within  seven  to  ten  days  after  the
nset  of  the  initial  signs  of  infection.6 It  is  possible  for  the
nﬁltrates  to  persist  for  extended  periods  of  time  ranging
rom  months  to  years,  and  their  presence  can  also  cause
educed  visual  acuity.4,12 A  study  by  Butt  and  Chodosh  found
hat  25.9%  of  patients  demonstrated  chronic  corneal  inﬂam-
ation  with  symptomatic  SEIs  present  for  more  than  45  days
rom  the  ﬁrst  examination.4
Accurate  diagnosis  of  EKC  upon  presentation  is
ssential.1,12 Misdiagnosis  can  lead  to  inaccurate  patient
xpectations  for  resolution,  as  well  as,  a  lack  of  patient
ducation  on  appropriate  disinfection  precautions.  Pre-
enting  the  spread  of  EKC  may  be  the  most  proactive
ay  of  treating  it.1 This  largely  depends  on  the  eye  care
ractitioner  making  the  correct  diagnosis  and  instituting
he  appropriate  treatment  before  the  patient  leaves  the
rovider’s  ofﬁce.1,12 The  patient  should  be  aware  that
KC  is  easily  transmitted  by  contact  with  an  inert  surface,
uch  as  a  door  handle,  and  to  avoid  rubbing  eyes  and
hen  touching  anything.9 Frequent  hand  washing  should
e  implemented  and  infected  patients  should  not  share
owels  or  cosmetics.15 Contact  lens  wearers  should  be  told
o  throw  away  their  disposable  lenses  and  use  a  new  pair
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Table  1  Universal  protection  control  procedures.16
(1)  Employ  proper  hand  washing  technique  before  and
after every  patient.
(2)  Use  disposable  medical  gloves  as  a  barrier  precaution
when in  contact  with  any  potentially  infectious  material.
(3) Use  gowns  and  masks  as  barrier  precautions  with  the
possibility  of  blood  splatter,  and  masks  if  an  airborne
pathogen  is  suspected.
(4)  Protective  eyewear  is  recommended  when
contaminated  ﬂuids  or  blood  could  splash  into  the
examiner’s  eyes.
(5)  Minimize  contact  with  infected  tissue  through  ‘‘no
touch’’  techniques  such  as  ﬁnger  cots,  cotton-tipped
applicators  or  other  instrumentation.
(6)  Dispose  of  sharps  instruments  in  appropriate  waste
containers.
(7) Instrument  disinfection  is  necessary  for  all  instruments
that  come  in  contact  with  the  ocular  adnexa,  including
the cornea  and  tears.
(8)  Instrument  sterilization  is  necessary  for  all  instruments
that  come  into  contact  with  the  vascular  system.
(9) Follow  contact  lens  disinfection  procedures
recommended  by  the  CDC.
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o(10)  Dispose  of  infectious  waste  according  to  federal,
state and  local  guidelines.
only  after  the  infection  has  cleared.15 The  patient  should
be  educated  that  the  contagious  period  for  EKC  may  last
upward  of  14  days  from  when  the  symptoms  began  and
caution  should  be  exercised  if  returning  to  school  or  work
before  that  time.13 Kaufman  recommends  that  health  care
providers  who  contract  adenoviral  conjunctivitis  spend  two
weeks  isolated  from  patient  care  in  order  to  prevent  the
spread  of  the  disease.12
Due  to  its  highly  contagious  nature,  an  outbreak  of  EKC  in
a  doctor’s  ofﬁce  can  have  a  snowball  effect,  quickly  spread-
ing  from  one  patient  to  the  next.12 A  proper  diagnosis  is
necessary  to  implement  extra  precautions  with  disinfection
procedures  and  decrease  patient  morbidity.3,12 Table  1  high-
lights  basic  protection  control  procedures  that  should  be
implemented  on  a  regular  basis  to  prevent  any  disease  trans-
mission,  including  EKC,  in  the  medical  provider’s  ofﬁce.16
When  available,  single-use  disposable  devices  should  be
employed  to  assist  in  the  examination  of  the  patient.15
This  includes  disposable  medical  gloves,  disposable  drop-
pers,  cotton-tipped  applicators  and  disposable  tonometer
prism  or  shields  that  can  all  be  discarded  immediately  after
use.15 A  tonopen  with  a  sterile,  disposable  tip  cover  would
be  a  practical  tool  to  use  upon  presentation  of  any  poten-
tially  contagious  conjunctivitis  patient.15 In  the  case  of
suspected  or  known  presence  of  adenovirus,  emphasis  can
also  be  placed  on  proper  disinfection  of  the  exam  room  and
any  instruments  that  came  into  contact  with  the  patient.15
Lakkis  et  al.  recommend  cleaning  all  large  surfaces  in  an
optometric  practice  with  isopropyl  alcohol  tissues,  30%  alco-
hol  solution  or  sodium  hypochlorite  solution  (obtained  with  a
1:5  dilution  of  5%  household  bleach).15 With  the  increasingly
common  use  of  electronic  health  records  in  today’s  practice,
it  is  also  recommended  to  wipe  computer  keyboards  with
alcohol  each  day.15
S
h
d
iFigure  2  Removal  of  pseudomembrane  secondary  to  EKC.
There  are  no  universal  guidelines  for  optometrists  in
egard  to  decontamination  of  ophthalmic  instruments.15
he  Centers  for  Disease  Control  (CDC)  has  published  an
xtensive  document  entitled  Guideline  for  Disinfection  and
terilization  in  Healthcare  Facilities,  2008  which  describes
vidence-based  recommendations  for  cleaning,  disinfection
nd  sterilization  of  medical  devices.17 Maximum  effective-
ess  for  infection  control  is  dependent  on  cleaning  as  the
nitial  step.17 Cleaning  is  deﬁned  as  removing  all  visible
rganic  and  inorganic  material  from  an  object  or  surface.17
nstruments  that  have  come  in  contact  with  mucous  mem-
rane  tissue  or  non-intact  skin  are  classiﬁed  by  the  CDC  as
‘semicritical  items’’  which  at  minimum  require  high-level
isinfection  using  chemical  disinfectants.17 The  CDC  recom-
ends  that  tonometer  tips  are  wiped  clean  and  disinfected
or  5--10  min  with  either  3%  hydrogen  peroxide,  5000  ppm
hlorine,  70%  ethyl  alcohol  or  70%  isopropyl  alcohol,  then
horoughly  rinsed  in  tap  water  and  air  dried  before  use.17
he  CDC  guidelines  document  recognizes  that  there  is  some
vidence  that  3%  hydrogen  peroxide  and  70%  isopropyl  alco-
ol  may  not  be  effective  against  EKC-causing  adenovirus.17
n  contrast,  one  study  showed  that  adenovirus  8  is  effec-
ively  eliminated  from  tonometer  tips  with  a  disinfectant
ipe  containing  isopropyl  alcohol,  hydrogen  peroxide  or
odopher.18 The  same  study  also  demonstrated  that  no  virus
as  recovered  from  Goldmann  tonometer  tips  following  a
-min  soak  in  the  same  disinfectants  that  composed  the
ipes.18 This  contradiction  may  exist  secondary  to  the  stud-
es  being  performed  in  a  controlled  laboratory  setting  and
urther  studies  are  needed  for  a  clear  recommendation.17
he  FDA  requests  the  manufacturers  of  medical  devices
o  include  at  least  one  validated  cleaning  and  disinfection
r  sterilization  protocol  in  the  labeling  of  their  devices.17
herefore,  it  has  been  suggested  to  refer  to  the  manu-
acturer’s  recommendations  for  protocol  on  disinfection  or
terilization  of  ophthalmic  instruments.15 Haag  Streit  details
 step-by-step  process  for  disinfecting  tonometer  tips  on  its
ebsite  and  Volk  Optical  Inc.  has  a  very  extensive  ‘‘Cleaning
 Care  Guide’’  on  its  website  that  provides  cleaning,  disin-
ection  and  sterilization  methods  for  its  various  lenses.19,20
he  CDC  classiﬁes  ‘‘critical  items’’  as  those  that  confer  a
igh  risk  for  infection  such  as  objects  that  enter  sterile  tissue
r  the  vascular  system.17 These  objects  must  undergo  steril-
zation  which  is  accomplished  with  steam,  or  heat-sensitive
bjects  may  be  treated  with  approved  chemical  sterilants.17
terilization  is  recommended  for  any  instruments  that  may
ave  come  in  contact  with  blood,  as  is  possible  with  pseu-
omembrane  removal  in  an  EKC  patient17 (see  Fig.  2).  These
nstruments  should  be  properly  cleaned  and  disinfected  ﬁrst,
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Table  2  Adenoviral  conjunctivitis  treatment
recommendations.26
Presence of a
pseudomembrane?
Yes No
-Peel pseudomembrane
-Topical steroids for 1
week, then  taper
-Palliave  treatment
(ATs, cool compresses)
SEIs aﬀecng
visual acuity?
Yes No
-Connue  palliave-Topical steroids for
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hen  wrapped  in  peel  pouches  and  sterilized  by  the  eye  care
rovider  in  ofﬁce  using  a  tabletop  steam  autoclave  unit.16
The  clinical  diagnosis  of  an  adenovirus  infection  is  typ-
cally  made  based  on  the  history  and  presenting  signs  and
ymptoms.3 In  reality,  it  may  initially  be  difﬁcult  to  clin-
cally  distinguish  some  viral  conjunctivitis  from  bacterial
onjunctivitis.1,3 The  traditional  gold  standard  for  diagno-
is  of  EKC  or  any  adenovirus  conjunctivitis  has  been  cell
ulture  in  combination  with  immunoﬂuorescence  staining
CC-IFA).1,3 Other  laboratory  diagnostic  methods  used  to
dentify  adenoviral  infections  include  serologic  methods,
ntigen  detection  and  polymerase  chain  reaction  (PCR).1,3
ome  consider  PCR  the  new  gold  standard  for  diagnosis
ecause  it  is  very  speciﬁc  and  has  proven  to  be  more  sen-
itive  than  CC-IFA.1,3 To  date  these  methods  are  the  most
ccurate  way  to  conﬁrm  the  cause  of  conjunctivitis;  how-
ver,  many  doctors’  ofﬁces  lack  direct  access  to  diagnostic
ab  procedures.1 Both  the  prohibitive  cost  and  time  delay  in
eferring  a  patient  out  for  laboratory  diagnostic  testing  and
hen  waiting  to  receive  the  outcome,  present  a  diagnostic
hallenge  to  physicians.3 The  result  of  this  dilemma  is  that
iagnostic  and  treatment  decisions  are  made  based  upon
resenting  signs  and  symptoms,  along  with  previous  clinical
xperience.3 Thus,  a  disease  with  a  presumed  etiology  may
isk  being  inadvertently  mistreated.
There  is  recognition  of  the  potential  beneﬁt  of  a  rapid
ccurate  diagnostic  test  to  help  identify  patients  pre-
enting  with  adenoviral  infection.9 Cheung’s  study  found
hat  standard  viral  culture  techniques  are  not  satisfactory
ue  to  the  time  it  takes  for  the  viral  culture  swabs  to  produce
 result.9 Rapid  diagnosis  of  infection  has  improved  with
on-culture-based  techniques.5 Sambursky  et  al.  report  the
ntroduction  of  the  Rapid  Pathogen  Screening  (RPS)  Adeno
etector  which  is  described  as  ‘‘a  rapid  point-of-care  diag-
ostic  test  for  the  visual,  qualitative  in  vitro  detection
f  adenoviral  antigens  directly  from  human  eye  ﬂuid.’’3
linical  research  suggests  that  a  sensitivity  of  88%  and
peciﬁcity  of  91%  in  comparison  to  CC-IFA  makes  the  RPS
deno  Detector  useful  for  in  ofﬁce  detection  of  adenovi-
al  conjunctivitis.3 The  RPS  Adeno  Detector  works  with  a
irect  sample  and  no  extraction  or  dilution  step  is  required.3
 ‘‘Point  of  Care’’  device  such  as  the  RPS  Adeno  Detector
ith  immediate  and  easy-to-read  results  may  prove  useful
n  determining  proper  diagnosis  of  in-ofﬁce  patients  whose
ases  are  not  already  evident.21
Despite  the  fact  that  EKC  is  a  self-limiting  disease,
ost  affected  individuals  seek  and  receive  treatment  as
 result  of  the  severity  of  their  symptoms.7 The  treat-
ent  of  EKC  often  includes  palliative  treatment,  such  as
ool  compresses  and  artiﬁcial  tears.6 In  various  instances,
KC  treatment  has  also  consisted  of  topical  antibiotics,
opical  nonsteroidal  anti-inﬂammatory  drugs  (NSAIDS)  and
opical  corticosteroids.4,6 Supportive  therapy  is  an  obvi-
us  choice  for  treatment  because  there  are  currently  no
pproved,  effective  anti-adenoviral  therapies.5,7,8 However,
ne  study  showed  that  36%  of  eye  care  practitioners  sur-
eyed  prescribed  topical  corticosteroids  to  treat  EKC.22
ost  clinicians  agree  that  clinical  use  of  topical  cortico-
teroids  is  justiﬁed  in  cases  of  acute  EKC  where  there
s  the  threat  of  incapacitating  visual  loss  from  persistent
ubepithelial  inﬁltrates,  pseudomembranous  conjunctivitis
nd  iridocyclitis.4,22--24 Steroids  suppress  conjunctival  and
i
c
atreatment1 week, then  taper
orneal  inﬂammation  to  provide  symptomatic  relief,  but
hey  do  not  act  to  shorten  the  course  of  EKC.25
It  is  important  to  recognize  the  risks  and  indications
or  proceeding  with  corticosteroids  when  treating  presumed
cular  viral  infections.  The  possibility  of  misdiagnosing  an
arly  presentation  of  herpes  simplex  type  I,  acanthamoeba
r  fungal  infection  in  combination  with  use  of  topical  cor-
icosteroids  could  be  detrimental  to  a  patient’s  ocular
ealth.23,25 The  increased  incidence  of  side  effects  from
ong-term  use  such  as  cataracts  and  glaucoma  should  be  con-
idered,  but  are  less  likely  to  be  a  factor  when  treating  acute
isease.23 When  corticosteroids  are  used,  they  are  often
eserved  until  patients  present  with  a  pseudomembrane
r  symptomatic  subepithelial  inﬁltrates4,26 (see  Table  2).
owever,  there  is  clinical  evidence  that  this  prolongs  the
uration  of  SEIs.4 The  literature  also  reports  that  both  long-
nd  short-term  use  of  topical  corticosteroids  enhances  ade-
ovirus  replication  and  prolongs  adenovirus  shedding.23,25
esearchers  have  suggested  that  normal  adenovirus  clear-
nce  is  inhibited  by  the  strong  anti-inﬂammatory  and
nti-immune  effects  of  the  corticosteroid.23 Romanowski
t  al.  demonstrated  in  numerous  experimental  studies  that
orticosteroids,  ranging  from  the  more  potent  1%  pred-
isolone  acetate  to  the  less  potent  0.12%  prednisolone
cetate,  all  increased  the  duration  of  viral  shedding  in  vary-
ng  degrees.23,25 One  of  these  studies  found  that  long-term
reatment  with  1%  prednisolone  acetate  profoundly  altered
mmune  clearance  and  could  potentially  increase  the  risk  of
ransmission  and  promote  the  number  and  extent  of  com-
unity  and  medical  facility  epidemics.25 Another  concluded
hat  the  risk  of  using  a  corticosteroid  and  prolonging  an
nfection  must  be  weighed  against  the  clinical  beneﬁt  of
hort-term  more  limited  potency  corticosteroids  used  for
ymptomatic  relief.23 The  controversial  use  of  corticoste-
oids  in  conjunction  with  EKC  treatment  would  not  need
o  be  a  consideration  with  the  development  of  an  anti-
nﬂammatory  therapeutic  that  does  not  inhibit  adenoviral
learance  or  an  effective  antiadenoviral  agent.
The  effects  of  non-steroidal  topical  therapeutics  on
denovirus  conjunctivitis  have  been  explored.  NSAIDS  do
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not  affect  adenovirus  clearance  but  have  demonstrated  no
better  relief  to  patient  symptoms  from  viral  conjunctivitis
than  artiﬁcial  tears.27,28 Cyclosporine  was  speciﬁcally
explored  for  treating  symptoms  caused  by  subepithelial
inﬁltrates.29,30 Though  one  study  found  subjective  improve-
ment  of  local  symptoms  with  1%  cyclosporine  eyedrops,
as  compared  to  0.2%  cidofovir  or  a  combination  of  0.2%
cidofovir  +  1%  cyclosporine;  no  acceleration  in  improvement
of  clinical  symptoms  was  found  compared  to  the  natural
course  of  the  EKC  infection.29 Romanowski  et  al.  found
that  treatment  with  both  2.0%  and  0.5%  cyclosporine  A  in
the  rabbit  model  signiﬁcantly  reduced  the  formation  of
SEI’s.30 However,  use  of  topical  cyclosporine  A  increased
adenoviral  replication,  similar  to  the  results  reported  with
corticosteroid  use.30
Research  has  been  directed  toward  the  treatment  of
adenoviral  keratoconjunctivitis  with  antiviral  compounds.
Ribavirin  has  been  explored  in  clinical  studies  and  was
found  to  have  restricted  in  vitro  activity  and  lack  efﬁ-
cacy  against  the  three  predominant  adenovirus  serotypes
associated  with  EKC  (Ad8,  Ad19  and  Ad37).7,8 Nucleoside
analogues  are  also  known  to  be  active  against  adenoviral
infections  and  examples  of  this  drug  class  include  cidofovir
and  ganciclovir.31 Success  in  cidofovir  studies  using  the  rab-
bit  model  led  to  clinical  trials  in  the  USA  to  investigate
cidofovir  against  human  ocular  adenovirus.8 An  early  study
by  Hillenkamp  showed  no  acceleration  in  improvement  of
EKC  clinical  symptoms  with  0.2%  cidofovir;  however  the
authors  speculated  that  the  concentration  of  cidofovir  was
too  low.29 Another  study  evaluating  the  efﬁcacy  of  cidofovir
1%  ophthalmic  preparation  with  and  without  cyclosporine
A  1%  demonstrated  that  cidofovir  decreases  the  frequency
of  severe  corneal  opacities.32 However,  its  clinical  use  was
deemed  limited  because  the  frequent  administration
was  associated  with  local  toxicity.32 Cidofovir  development
has  been  stopped  in  the  USA  secondary  to  clinical  concerns
about  its  toxicity  and  because  of  evidence  regarding  possible
emergence  of  clinical  resistance.8
Topical  ganciclovir  0.15%  ophthalmic  gel  is  now  avail-
able  commercially  in  the  United  States.  With  topical
administration,  ganciclovir  0.15%  ophthalmic  gel  achieves
therapeutic  levels  in  the  aqueous  and  cornea  and  is  a  known
effective  treatment  for  herpetic  epithelial  keratitis.33 Gan-
ciclovir  has  been  advocated  for  ‘off-label’  use  against  EKC
because  it  has  shown  potential  against  speciﬁc  adenovi-
rus  serotypes  in  vitro.8 A  study  in  Saudi  Arabia  compared
the  effects  of  ganciclovir  0.15%  ophthalmic  ointment
with  preservative-free  artiﬁcial  tears  for  18  patients  with
adenovirus  keratoconjunctivitis.34 The  ganciclovir  group
demonstrated  resolution  of  the  conjunctivitis  in  7.7  days,
as  opposed  to  18.5  days  for  the  artiﬁcial  tears  patients.34
Additionally,  only  two  of  the  cases  treated  with  ganciclovir
developed  subepithelial  opacities  while  their  presence  was
detected  in  seven  cases  treated  with  artiﬁcial  tears.34 The
authors  of  this  study  determined  that  topical  ganciclovir
0.15%  ophthalmic  ointment  is  safe  and  effective  for  the
treatment  of  adenoviral  conjunctivitis.34 The  effects  of
ganciclovir  on  adenoviral  keratoconjunctivitis  need  to  be
demonstrated  on  a  larger  scale  as  well  as  show  its  effectivity
against  adenoviral  strains  seen  in  other  countries.12
Promising  results  have  been  noted  in  the  treatment
of  adenovirus  conjunctivitis  with  povidone-iodine  (PVP-I).
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linical  practice  has  seen  the  use  of  ocular  applica-
ions  of  povidone-iodine  in  various  capacities  including
re-  and  postoperative  ocular  surgical  prophylaxis,  preven-
ion  of  neonatal  conjunctivitis  and  treatment  for  bacterial
onjunctivitis.35--37 Povidone-iodine  has  a  broad  antimicro-
ial  spectrum  in  vitro  and  effectively  kills  bacteria,  fungi,
iruses  and  protozoa.35,36 A  study  by  Pelletier  et  al.  inves-
igated  a  topical  combination  agent  that  contained  0.4%
ovidone-iodine  as  an  anti-viral  and  0.1%  dexamethasone
s  a  potent  steroid.37 The  expectation  of  the  study  was
o  ‘‘effectively  treat  both  the  inﬂammatory  and  infectious
omponents  of  acute  adenoviral  conjunctivitis  by  decreasing
he  symptomatic  period  following  infection,  shortening  the
uration  of  viral  shedding  and  reducing  the  potential  for
nfectious  transmission.’’37 The  study  followed  the  clinical
ourse  of  positive  RPS  Adeno  Detector  conjunctivitis  while
onitoring  serial  virology  markers  by  quantitative  PCR  and
C-IFA.37 The  results  demonstrated  that  all  eyes  had  rapid
mprovement  of  conjunctival  injection  and  discharge  with
 decrease  in  viral  titers  at  the  same  time,  warranting  a
eed  for  further  study  of  this  combination  agent.37 The
uthors  of  another  study  conﬁrmed  ‘‘the  efﬁcacy  of  top-
cal  dexamethasone  0.1%/povidone-iodine  0.4%  (FST-100)
n  reducing  clinical  symptoms  and  infectious  viral  titers  in
 rabbit  model  of  adenoviral  keratoconjunctivitis.’’38 This
tudy  concluded  that  FST-100  has  the  potential  to  become
he  preferred  drug  in  treating  adenoviral  conjunctivitis  in
umans  and  could  be  most  effective  in  the  treatment  of
ore  serious  forms  of  infection,  including  EKC.38 Reports  of
ff-label  use  of  povidone-iodine  have  also  claimed  to  pre-
erve  visual  function  and  reduce  viral  spread.39 One  protocol
alls  for  the  medical  provider  to  anesthetize  the  affected
ye,  instill  a  pretreatment  NSAID,  then  instill  four  to  ﬁve
rops  of  5%  povidone-iodine  solution,  have  the  patient  roll
is  or  her  eyes  around  for  full  exposure,  swab  the  lid  margins
ith  the  solution  while  the  patient  waits  for  approximately
0  s  and  ﬁnally  lavage  the  ocular  tissue  with  sterile  saline
rrigating  solution.39 Development  continues  of  various  com-
ounds  that  have  demonstrated  anti-adenoviral  activity.  The
ndogenous  microbicide  agent  N-chlorotaurine  has  shown
vidence  of  antimicrobial  activity  against  EKC  and  was  also
ell-tolerated  with  minimal  side  effects.40,41 There  is  clearly
 need  for  a  potent  anti-viral  drug  that  addresses  patient
ymptoms,  prevents  SEI  formation  and  does  not  interfere
ith  viral  clearance.30
onclusion
ntil  an  effective  antiviral  or  a  better  alternative  to  treat
KC  becomes  available,  clinicians  must  be  cautious  in  their
se  of  corticosteroids.  Eye  care  providers  must  carefully
onsider  the  risks  involved  with  the  use  of  a corticosteroid
or  symptomatic  relief  of  EKC  and  its  potential  to  prolong  an
nfection.  The  extended  period  of  adenovirus  shedding  asso-
iated  with  the  use  of  corticosteroids  could  also  enhance
he  spread  of  EKC  and  lead  to  increased  local  epidemics.
ven  with  the  current  limited  treatment  options  for  EKC,
he  fact  still  remains  that  intervention  is  required  dur-
ng  the  viral  replication  stage,  and  patients  often  do  not
olicit  medical  consultation  until  the  inﬂammatory  man-
festations  interfere  with  their  daily  activities.  Eye  care
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roviders  should  be  aware  that  their  management  decisions
n  treating  adenoviral  conjunctivitis  play  a  very  important
ole  in  containing  epidemics  and  minimizing  patient  mor-
idity.  While  the  search  for  anti-viral  therapy  with  better
fﬁcacy  and  minimal  side-effects  continues,  the  manage-
ent  of  EKC  will  continue  to  present  a  clinical  dilemma.
ccurate  diagnosis  and  prevention  of  transmission  should  be
tressed  as  the  ﬁrst  line  of  defense  available  to  contain  the
issemination  of  EKC.  The  current  therapeutic  treatment
egimen  for  an  EKC  patient’s  signs  and  symptoms  needs  to
aintain  a  judicious  case-by-case  approach  to  prevent  any
isual  consequence(s).
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